Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer.

Christopher A LemmonEmily C ZaborNathan A Pennell

Published in: The oncologist (2022)

Three-years of adjuvant osimertinib is CE if one is willing to pay $317 119 more per QALY-gained. Considerable OS benefit over placebo or other economic interventions will be needed to reach CE.

Keyphrases

small cell lung cancer
epidermal growth factor receptor
advanced non small cell lung cancer
early stage
tyrosine kinase
energy transfer
physical activity
lymph node
health insurance
randomized controlled trial
double blind
clinical trial
study protocol
open label